EGFR and lung adenocarcinoma: Surprisingly, c-Src inactivation through caspase-8 knockdown or dasatinib was able to block the survival-signaling-related tyrosine phosphorylation of EGFR, which, in turn, increased the antitumor activity of TKIs in EGFR-mutant lung adenocarcinoma.